A possible role for nitric oxide in osteoclastogenesis associated with cholesteatoma

Otology and Neurotology

Volumn 25, Issue 5, 2004, Pages 661-668

  Jung, Jae Y ^a,b   Pashia, Mary E ^a   Nishimoto, Sheri Y ^a   Faddis, Brian T ^a   Chole, Richard A ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Cholesteatoma; Inflammation; Nitric oxide; Osteoclast; Osteolysis

Indexed keywords

AMINOGUANIDINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; KERATIN; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CHOLESTEATOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HEARING LOSS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VESTIBULAR DISORDER;

ANIMALS; BONE RESORPTION; CELLS, CULTURED; CHOLESTEATOMA; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANIDINES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OSTEOCLASTS; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544363133     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200409000-00003     Document Type: Article

References (38)

1. Chole RA. The molecular biology of bone resorption due to chronic otitis media. Ann N Y Acad Sci 1997;830:95-109.
2. Jung JY, Chole RA. Bone resorption in chronic otitis media: the role of the osteoclast. ORL J Otorhinolaryngol Relat Spec 2002; 64:95-107.
3. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. Am J Otol 1998;19:7-19.
4. Sudhoff H, Dazert S, Gonzales AM, et al. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma. Am J Otol 2000;21:793-8.
5. Akimoto R, Pawankar R, Yagi T, et al. Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. ORL J Otorhinolaryngol Relat Spec 2000;62:257-65.
6. Kim CS, Lee CH, Chung JW, et al. Interleukin-1 alpha, interleukin-1 beta and interleukin-8 gene expression in human aural cholesteatomas. Acta Otolaryngol 1996;116:302-6.
7. Ryan AF, Bennett T. Nitric oxide contributes to control of effusion in experimental otitis media. Laryngoscope 2001;111:301-5.
8. Rose AS, Prazma J, Randell SH, et al. Nitric oxide mediates mucin secretion in endotoxin-induced otitis media with effusion. Otolaryngol Head Neck Surg 1997;116:308-16.
9. Hebda PA, Burckar GJ, Alper CM, et al. Effect of 10 pharmacologic probes on mRNA levels of inducible nitric oxide synthetase and selected inflammatory cytokines in a rat model of acute otitis media. Acta Otolaryngol 2002;122:255-61.
10. Andrew PJ, Harant H, Lindley IJ. Up-regulation of interleukin-1 beta-stimulated interleukin-8 in human keratinocytes by nitric oxide. Biochem Pharmacol 1999;57:1423-9.
11. van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001;103:255-61.
12. Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem 1995;57:399-408.
13. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998;17:7-23.
14. Wimalawansa SJ, Chapa MT, Yallampalli C, et al. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone 1997;21:275-80.
15. Wimalawansa SJ, De Marco G, Gangula P, et al. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996;18: 301-4.
16. Tsukahara H, Miura M, Tsuchida S, et al. Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats. Am J Physiol 1996;270:E840-5.
17. Kasten TP, Collin-Osdoby P, Patel N, et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA 1994;91:3569-73.
18. Chole RA, Tinling SP, Leverentz E, et al. Inhibition of nitric oxide synthase blocks osteoclastic bone resorption in adaptive bone modeling. Acta Otolaryngol 1998;118:705-11.
19. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105:433-40.
20. Merkel KD, Erdmann JM, McHugh KP, et al. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999;154:203-10.
21. Chole RA, Hughes RM, Faddis BT. Keratin particle-induced osteolysis: a mouse model of inflammatory bone remodeling related to cholesteatoma. J Assoc Res Otolaryngol 2001;2:65-71.
22. Green TR, Fisher J, Stone M, et al. Polyethylene particles of a 'critical size' are necessary for the induction of cytokines by macrophages in vitro. Biomaterials 1998;19:2297-302.
23. Applied Biosystems. User Bulletin #2: ABI prism 7700 sequence detection system. Foster City, CA: Applied Biosystems, 2001;1-36.
24. Holliday LS, Dean AD, Lin RH, et al. Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am J Physiol 1997;272:F283-91.
25. Feelisch M, Stamler J. Methods in Nitric Oxide Research. New York: John Wiley & Sons, 1996, 303-7.
26. Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-6.
27. van't Hof RJ, Armour KJ, Smith LM, et al. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci USA 2000;97:7993-8.
28. Leeuwenkamp OR, Van Bennekom WP, Van der Mark EJ, et al. Nitroprusside, antihypertensive drug and analytical reagent. Review of (photo)stability, pharmacology and analytical properties. Pharm Weekbl Sci 1984;6:129-40.
29. Yeates RA, Laufen H, Leitold M. The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates. Mol. Pharmacol 1985;28:555-9.
30. Calabrese EJ. Nitric oxide: biphasic dose responses. Crit Rev Toxicol 2001;31:489-501.
31. Jung JY, Lin AC, Ramos LM, et al. Nitric oxide synthase I mediates osteoclast activity in vitro and in vivo. J Cell Biochem 2003;89:613-21.
32. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-5.
33. Watanuki M, Sakai A, Sakata T, et al. Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J Bone Miner Res 2002;17:1015-25.
34. Huang PL, Fishman MC. Genetic analysis of nitric oxide synthase isoforms: targeted mutation in mice. J Mol Med 1996;74:415-21.
35. Zaman G, Pitsillides AA, Rawlinson SC, et al. Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J Bone Miner Res 1999; 14:1123-31.
36. Koyama A, Otsuka E, Inoue A, et al. Nitric oxide accelerates the ascorbic acid-induced osteoblastic differentiation of mouse stromal ST2 cells by stimulating the production of prostaglandin E(2). Eur J Pharmacol 2000;391:225-31.
37. Brenman JE, Chao DS, Gee SH, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains. Cell 1996;.84:757-67.
38. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001;81:209-37.